Metagenomi Therapeutics, Inc. (MGX)

Metagenomi Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-87.87	-78.06	-68.26	-43.59	-21.44
Depreciation & Amortization	5.32	5.41	4.21	1.73	0.39
Stock-Based Compensation	11.85	16.2	6.92	1.96	0.38
Other Adjustments	3.9	7.04	-7.85	0.14	-1.32
Change in Receivables	0.95	1.19	-2.45	-	-
Changes in Accounts Payable	1.05	-1.11	-0.08	0.72	0.7
Changes in Accrued Expenses	-1.64	-0.89	1.63	4.53	1.85
Changes in Income Taxes Payable	-	-3.27	1.73	1.54	-
Changes in Unearned Revenue	-21.1	-46.8	-30.3	65.66	44.23
Changes in Other Operating Activities	-1.36	-8.79	3.04	-2.96	-0.52
Operating Cash Flow	-88.89	-109.07	-91.41	29.72	24.26
Operating Cash Flow Growth	-	-	-	22.54%	-
Capital Expenditures	-0.57	-3.11	-9.81	-13.98	-2.9
Sale of Property, Plant & Equipment	0.04	-	-	-	-
Purchases of Investments	-66.41	-306.42	-208.1	-214.85	-71.41
Proceeds from Sale of Investments	170.47	221.38	263.64	106.63	-
Investing Cash Flow	103.53	-88.16	45.73	-122.2	-74.32
Issuance of Common Stock	0.2	84.01	-	-	-
Net Common Stock Issued (Repurchased)	0.2	84.01	-	-	-
Issuance of Preferred Stock	-	-	4.3	239.59	9.95
Net Preferred Stock Issued (Repurchased)	-	-	4.3	239.59	9.95
Other Financing Activities	-0.56	-	-3.28	-	29.97
Financing Cash Flow	-0.36	84.01	1.01	239.59	39.92
Net Cash Flow	14.28	-113.22	-44.66	147.12	-10.14
Free Cash Flow	-89.47	-112.19	-101.22	15.75	21.35
Free Cash Flow Growth	-	-	-	-26.26%	-
FCF Margin	-354.88%	-214.53%	-226.17%	91.55%	8787.65%
Free Cash Flow Per Share	-2.40	-3.40	-29.73	4.63	-
Levered Free Cash Flow	-106.17	-136.63	-97.84	13.65	22.3
Unlevered Free Cash Flow	-114.25	-141.61	-118.54	9.81	19.79

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q